List of Excipients in Branded Drug INQOVI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Taiho Pharmaceutical Co Ltd	INQOVI	cedazuridine and decitabine	64842-0727	CROSCARMELLOSE SODIUM	2041-02-24
Taiho Pharmaceutical Co Ltd	INQOVI	cedazuridine and decitabine	64842-0727	FERRIC OXIDE RED	2041-02-24
Taiho Pharmaceutical Co Ltd	INQOVI	cedazuridine and decitabine	64842-0727	HYPROMELLOSE	2041-02-24

Inqovi Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Inqovi is an oral fixed-dose tablet combining decitabine and cedazuridine. The product uses a conventional immediate-release solid-dose formulation, but its commercial value depends on more than the active ingredients. Excipient selection supports chemical stability, tablet manufacturability, dose uniformity, swallowability, and the regulatory bridge between oral decitabine and intravenous decitabine.

The main commercial opportunity is not a novel excipient platform. It is supplying high-quality, compendial excipients and developing differentiated oral solid-dose products that address generic entry, manufacturing robustness, patient tolerability, and potential lifecycle extensions.

What is Inqovi and how is it formulated?

Inqovi is a 35 mg decitabine/100 mg cedazuridine film-coated tablet approved by the U.S. Food and Drug Administration in July 2020 for adults with myelodysplastic syndromes, including previously untreated and previously treated disease, and chronic myelomonocytic leukemia [1].

Inqovi composition

The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Function
Lactose monohydrate	Diluent and tablet-mass builder
Hypromellose	Binder and film-forming polymer
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and moisture-management aid
Magnesium stearate	Lubricant
Talc	Processing aid and coating component
Polyvinyl alcohol	Film-coating polymer
Titanium dioxide	Opacifier and colorant
Polyethylene glycol	Plasticizer in the film coat

The tablet is designed for oral administration without reconstitution, infusion equipment, or parenteral administration. Its excipient system is therefore aligned with standard immediate-release tablet manufacturing rather than modified release, enteric delivery, or lipid-based delivery.

Why the formulation matters

Decitabine is sensitive to degradation in solution and has historically required intravenous administration. Cedazuridine inhibits cytidine deaminase, an enzyme that limits the systemic exposure of orally administered decitabine. The fixed-dose tablet depends on consistent dissolution and absorption to generate clinically relevant systemic decitabine exposure [1,2].

The excipient system must therefore support:

• Rapid tablet disintegration.
• Reliable dissolution of both active ingredients.
• Low variability in dose uniformity.
• Protection from moisture and handling stress.
• Compatibility with a potent cytotoxic active ingredient.
• Stable commercial-scale compression and coating.

The formulation does not require a complex delivery technology. That reduces manufacturing barriers but also limits differentiation based solely on excipient innovation.

What excipient functions are most important in Inqovi?

Lactose monohydrate as the principal diluent

Lactose monohydrate provides bulk and improves compression characteristics. Its use indicates that the formulation requires a conventional filler to achieve an acceptable tablet size at the 135 mg total active load.

Commercial suppliers can compete on:

• Low endotoxin and bioburden performance.
• Particle-size distribution.
• Flowability.
• Moisture control.
• Lot-to-lot compressibility.
• Documentation for global regulatory filings.

Lactose creates a potential patient-management issue for individuals with severe lactose intolerance, although the amount in a tablet is generally much lower than dietary lactose exposure. A lactose-free version could have commercial value if it preserves tablet hardness, disintegration, and stability without increasing tablet size.

Hypromellose and polyvinyl alcohol in coating and binding

Hypromellose supports tablet cohesion and may also be used in the coating system. Polyvinyl alcohol is a standard film-forming polymer that improves tablet appearance, handling, and protection from environmental exposure.

A formulation developer seeking to design an equivalent product could evaluate:

• Hypromellose grade and viscosity.
• Polyvinyl alcohol molecular-weight distribution.
• Coating weight gain.
• Plasticizer level.
• Coating porosity.
• Water-vapor transmission.
• Colorant and opacity requirements.

The main technical risk is changing the dissolution profile while attempting to optimize coating performance. A thicker or less permeable coating could slow release. A more porous coating could provide weaker moisture protection.

Croscarmellose sodium as the disintegration control

Croscarmellose sodium is the principal superdisintegrant disclosed for the product. It promotes tablet breakup after ingestion and helps expose the active pharmaceutical ingredients to gastrointestinal fluid.

Its performance depends on:

• Substitution level.
• Fiber morphology.
• Particle size.
• Intra- versus extra-granular distribution.
• Compression force.
• Tablet porosity.
• Moisture content.

A generic manufacturer could improve process robustness by optimizing the distribution of croscarmellose sodium between the granulation and final blending stages. However, changes must be evaluated against comparative dissolution, hardness, friability, and stability requirements.

Colloidal silicon dioxide and magnesium stearate

Colloidal silicon dioxide improves powder flow and can reduce blend segregation. Magnesium stearate reduces adhesion to punches and tooling.

Both excipients can create manufacturing tradeoffs. Excessive magnesium stearate or prolonged lubrication can reduce tablet wettability and slow dissolution. Excessive colloidal silicon dioxide can affect blend density and compression behavior.

The commercial opportunity is strongest for excipient grades with consistent surface area, low moisture, reliable flow, and predictable lubrication performance. Supplier value is based on process capability and technical support rather than chemical novelty.

What excipient patents protect Inqovi?

The commercial protection for Inqovi is more likely to center on the decitabine-cedazuridine combination, dosing regimen, oral administration, and pharmacokinetic or therapeutic use than on the disclosed excipients themselves.

Protection category	Relevance to Inqovi
Active-ingredient combination	Protects the use of decitabine with cedazuridine
Oral dosing regimen	Supports the clinical and commercial positioning of the tablet
Pharmacokinetic bridging	Links oral exposure with parenteral decitabine exposure
Tablet composition	May protect defined ranges or manufacturing parameters if claimed
Method of treatment	Covers treatment of myelodysplastic syndromes and related disorders
Manufacturing process	May address blending, compression, coating, or stability

The FDA label identifies the approved formulation and inactive ingredients but does not establish the full scope of any patent claims [1]. Excipient suppliers should distinguish between freedom to supply an excipient and freedom to commercialize a finished Inqovi-equivalent product. Supplying lactose, hypromellose, croscarmellose sodium, or magnesium stearate generally does not by itself create an infringement position tied to the finished drug’s use patents.

Are excipient substitutions commercially viable?

Yes, but substitution must preserve the product’s critical quality attributes. Potential substitutions include:

• Lactose monohydrate replaced by microcrystalline cellulose or mannitol.
• Hypromellose replaced by another compendial binder.
• Croscarmellose sodium replaced by sodium starch glycolate or crospovidone.
• Polyvinyl alcohol coating replaced by a different immediate-release coating system.

These substitutions may be technically feasible but can increase development risk. In an abbreviated new drug application, the applicant must demonstrate pharmaceutical equivalence and bioequivalence. A formulation that changes excipient composition can trigger additional comparative dissolution, stability, and bioequivalence work.

When does Inqovi lose exclusivity?

Inqovi has several distinct exclusivity layers:

Exclusivity category	Position
FDA approval	July 7, 2020
New chemical entity exclusivity	Not applicable in the conventional sense because decitabine and cedazuridine were previously known active ingredients
Orphan-drug status	Relevant if the approved indications received orphan designation and exclusivity
Patent protection	Depends on the patents listed for the product and their adjusted expiration dates
Regulatory exclusivity	Depends on orphan, pediatric, and other applicable protections

Inqovi’s commercial exclusivity is not determined by the active ingredients alone. Decitabine was previously approved as Dacogen, while cedazuridine had no equivalent standalone oncology product in the United States. The combination’s protection therefore depends heavily on patents and indication-specific regulatory rights.

The commercial loss-of-exclusivity date should be determined from the current FDA Orange Book, patent-term-adjustment data, pediatric extensions, orphan-designation records, and any Paragraph IV litigation outcomes [3,4]. A single nominal patent expiration date does not necessarily establish the first lawful generic launch date.

What is the Orange Book status of Inqovi?

Inqovi is an FDA-approved prescription drug product listed in the FDA’s drug databases. The Orange Book is the controlling source for listed patents, expiration information, and any associated exclusivity entries applicable to an ANDA applicant [3].

For commercial diligence, the relevant questions are:

1. Which patents are currently listed for Inqovi?
2. Are the listed patents active, expired, or subject to pediatric extension?
3. Do the claims cover the tablet, the combination, the dosing regimen, or treatment methods?
4. Has any ANDA applicant submitted a Paragraph IV certification?
5. Has the patent holder filed suit within the statutory 45-day period?
6. Has a settlement established a licensed or delayed generic-entry date?

Patent listings can change through FDA updates, patent-term calculations, litigation, and regulatory submissions. A generic manufacturer should not infer launch timing solely from the drug’s approval date or the earliest apparent patent expiration.

Which companies are challenging Inqovi exclusivity?

Publicly reported generic challenges must be assessed through FDA Orange Book records, ANDA litigation dockets, and federal court filings. The principal commercial parties associated with Inqovi are Taiho Pharmaceutical and its affiliates, which commercialize the product, and the original development organizations associated with decitabine and cedazuridine.

A complete competitive review should monitor:

• ANDA Paragraph IV notices.
• Hatch-Waxman complaints.
• Patent-listing disputes.
• Declaratory-judgment actions.
• Inter partes review petitions.
• Generic launch-at-risk announcements.
• Authorized-generic arrangements.
• Settlement agreements with licensed entry dates.

Without a verified current litigation docket, no specific generic challenger or settlement date should be treated as established.

What generic entry risks exist for Inqovi?

Inqovi faces several generic-entry pathways.

Conventional ANDA entry

A generic applicant may seek to demonstrate pharmaceutical equivalence and bioequivalence to the 35 mg/100 mg tablet. The main formulation-development targets are:

• Matching active-ingredient strength.
• Matching dosage form and route.
• Comparable dissolution across pH conditions.
• Comparable impurity profile.
• Comparable stability.
• Comparable tablet dimensions and performance where relevant.

The use of widely available compendial excipients lowers supply-chain barriers. It also makes it easier for generic manufacturers to construct alternative formulations.

Formulation-arounds

A formulation-around could use a different filler, binder, superdisintegrant, lubricant, or coating polymer. The strongest candidates would preserve immediate release while reducing dependence on lactose or a particular coating platform.

The principal risks are:

• Slower dissolution.
• Increased tablet size.
• Higher moisture sensitivity.
• Compression defects.
• Changes in exposure to decitabine or cedazuridine.
• Additional bioequivalence studies.

505(b)(2) or alternative oral products

A modified product could pursue a 505(b)(2) strategy if it introduces a new dosage form, strength, administration method, or formulation with reliance on existing findings. Potential concepts include:

• Lactose-free tablets.
• Orally disintegrating tablets.
• Sprinkle formulations.
• Lower-strength tablets for dose flexibility.
• Packaging systems that improve moisture protection.
• Alternative film coatings for swallowing or identification.

These products would need a clear clinical and regulatory rationale. A simple excipient substitution is more likely to fit an ANDA strategy than a 505(b)(2) pathway.

What are the best commercial opportunities in Inqovi excipients?

High-value excipient supply

The most immediate opportunity is supplying consistent grades of:

• Lactose monohydrate.
• Croscarmellose sodium.
• Hypromellose.
• Colloidal silicon dioxide.
• Magnesium stearate.
• Polyvinyl alcohol.
• Polyethylene glycol.

Manufacturers can differentiate through direct compression performance, low-moisture grades, technical services, regulatory documentation, and dual-region manufacturing capacity.

Lactose-free reformulation

A lactose-free formulation could address a defined patient segment and reduce dependence on the incumbent excipient system. Microcrystalline cellulose, mannitol, or a co-processed filler may provide alternatives.

The commercial case depends on whether the reformulated product can maintain tablet size and dissolution without requiring new clinical evidence beyond what the selected regulatory pathway demands.

Stability-enhancing packaging and coatings

Decitabine’s chemical stability makes moisture management commercially relevant. Opportunities include:

• High-barrier blister packaging.
• Desiccant-integrated bottles.
• Low-permeability film coats.
• Improved container-closure systems.
• Packaging that reduces tablet exposure during repeated opening.

These technologies may provide more defensible differentiation than replacing a standard filler.

Contract development and manufacturing

CDMOs with expertise in potent oncology compounds, low-dose blend uniformity, high-containment compression, and film coating can target Inqovi-related development programs. The fixed-dose combination requires controls for two active ingredients with different properties and a final product that supports reliable oral exposure.

How does Inqovi compare with intravenous decitabine?

Attribute	Inqovi	Intravenous decitabine
Active ingredients	Decitabine plus cedazuridine	Decitabine
Administration	Oral tablet	Intravenous infusion
Main excipient opportunity	Immediate-release tablet and coating	Parenteral formulation and reconstitution
Administration burden	Lower	Higher
Manufacturing focus	Blend uniformity, dissolution, moisture control	Sterility, reconstitution, stability after preparation
Generic complexity	Oral bioequivalence and formulation matching	Sterile manufacturing and injectable equivalence
Commercial differentiation	Convenience and fixed-dose delivery	Established parenteral use and clinical familiarity

Inqovi’s excipient strategy supports a lower-burden administration route. The commercial advantage is linked to oral convenience, while the technical burden shifts toward solid-dose uniformity, stability, and bioequivalence.

How strong is the Inqovi formulation estate?

The formulation estate appears commercially meaningful but less technically difficult to design around than a proprietary delivery system. The disclosed excipients are standard pharmaceutical ingredients. Their combination may be claimed in patent filings, but standard excipients generally do not create a high barrier unless the claims require narrow quantitative ranges, specific manufacturing conditions, or a demonstrated stability or pharmacokinetic effect.

The strongest protection is likely to arise from:

• The decitabine-cedazuridine combination.
• Oral dosing regimens.
• Treatment methods.
• Exposure relationships between cedazuridine inhibition and decitabine pharmacokinetics.
• Product-specific claims that link composition to performance.

For investors and licensees, the key distinction is between a conventional excipient system and a difficult-to-reproduce finished product. Inqovi is more defensible as a regulated combination therapy than as an excipient innovation.

Key Takeaways

• Inqovi is a 35 mg/100 mg immediate-release film-coated tablet containing decitabine and cedazuridine.
• Its excipient system uses conventional materials: lactose, hypromellose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and standard coating components.
• The main technical priorities are rapid disintegration, dissolution consistency, moisture control, and blend uniformity.
• Excipient suppliers have opportunities in high-consistency grades, regulatory support, moisture management, and dual-source supply.
• Lactose-free reformulation and improved packaging are the clearest lifecycle opportunities.
• Generic entry risk is meaningful because the formulation uses widely available compendial excipients.
• The strongest intellectual-property position is likely to reside in the active combination, dosing regimen, pharmacokinetics, and treatment methods rather than in the individual excipients.
• Current Orange Book listings and Hatch-Waxman litigation determine the practical launch timeline for generic competitors.

FAQs

Can Inqovi be reformulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, or a co-processed filler. The reformulation must preserve dissolution, stability, tablet strength, and bioequivalence.

Which excipient is most important for Inqovi disintegration?

Croscarmellose sodium is the primary disclosed superdisintegrant. Its grade, concentration, and intra- or extra-granular placement can materially affect tablet breakup and dissolution.

Is Inqovi an extended-release formulation?

No. Inqovi is an immediate-release film-coated tablet. Its commercial formulation strategy is based on rapid release and systemic exposure rather than controlled delivery.

Could an authorized generic use different excipients?

Potentially. An authorized generic may use the reference product’s formulation or a formulation that meets applicable regulatory requirements. The commercial and legal analysis depends on the authorization structure and patent position.

Do Inqovi excipients create a major generic manufacturing barrier?

No. The disclosed excipients are broadly available and widely used in oral solid dosage manufacturing. The more important barriers are bioequivalence, active-ingredient sourcing, patent rights, stability, and oncology-product regulatory execution.

References

1. U.S. Food and Drug Administration. (2024). Inqovi (decitabine and cedazuridine) tablets: Prescribing information.
2. Savona, M. R., et al. (2020). Oral decitabine and cedazuridine for myelodysplastic syndromes and chronic myelomonocytic leukemia. Blood, 136(6), 674-683.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.